phloretin has been researched along with Fatty Liver, Nonalcoholic in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD) with growing incidences is a major health concern worldwide." | 5.72 | Phloretin mitigates oxidative injury, inflammation, and fibrogenic responses via restoration of autophagic flux in in vitro and preclinical models of NAFLD. ( Chhimwal, J; Goel, A; Padwad, Y; Patial, V; Sukapaka, M, 2022) |
| "Phloretin (Ph) is a natural phenolic compound, that exhibits a wide array of pharmacological actions including its efficacy towards NAFLD." | 1.91 | Amorphous solid dispersion augments the bioavailability of phloretin and its therapeutic efficacy via targeting mTOR/SREBP-1c axis in NAFLD mice. ( Anand, P; Chhimwal, J; Dhritlahre, RK; Padwad, YS; Patial, V; Saneja, A, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) with growing incidences is a major health concern worldwide." | 1.72 | Phloretin mitigates oxidative injury, inflammation, and fibrogenic responses via restoration of autophagic flux in in vitro and preclinical models of NAFLD. ( Chhimwal, J; Goel, A; Padwad, Y; Patial, V; Sukapaka, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chhimwal, J | 2 |
| Goel, A | 1 |
| Sukapaka, M | 1 |
| Patial, V | 2 |
| Padwad, Y | 1 |
| Dhritlahre, RK | 1 |
| Anand, P | 1 |
| Saneja, A | 1 |
| Padwad, YS | 1 |
2 other studies available for phloretin and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Phloretin mitigates oxidative injury, inflammation, and fibrogenic responses via restoration of autophagic flux in in vitro and preclinical models of NAFLD.
Topics: Animals; Autophagy; Diet, High-Fat; Fatty Acids; Inflammation; Liver; Mice; Mice, Inbred C57BL; Non- | 2022 |
Amorphous solid dispersion augments the bioavailability of phloretin and its therapeutic efficacy via targeting mTOR/SREBP-1c axis in NAFLD mice.
Topics: Animals; Biological Availability; Lipids; Mice; Non-alcoholic Fatty Liver Disease; Phloretin; Spectr | 2023 |